Featured News See All November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA November 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 November 6, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Year All202420232022202120202019201820172016201520142013201220112009 Mar 06, 2024 REGENXBIO Announces Proposed Public Offering of Common Stock Mar 05, 2024 REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL Feb 29, 2024 REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial Feb 27, 2024 REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights Feb 21, 2024 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights Feb 07, 2024 REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint Feb 07, 2024 REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
Feb 29, 2024 REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
Feb 27, 2024 REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Feb 21, 2024 REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Feb 07, 2024 REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
Feb 07, 2024 REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial
